| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma
|
Abuhelwa, Ahmad Y.
|
|
|
89 |
4 |
p. 479-485
|
artikel
|
| 2 |
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point
|
Ferrer, Florent
|
|
|
89 |
4 |
p. 565-569
|
artikel
|
| 3 |
Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
|
Wang, Bei
|
|
|
89 |
4 |
p. 571-572
|
artikel
|
| 4 |
Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models
|
DeAngelis, Nikki
|
|
|
89 |
4 |
p. 515-527
|
artikel
|
| 5 |
Disulfiram/copper induces antitumor activity against gastric cancer cells in vitro and in vivo by inhibiting S6K1 and c-Myc
|
Du, Cheng
|
|
|
89 |
4 |
p. 451-458
|
artikel
|
| 6 |
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients
|
Takahashi, Takuto
|
|
|
89 |
4 |
p. 543-549
|
artikel
|
| 7 |
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
|
Felip, Enriqueta
|
|
|
89 |
4 |
p. 499-514
|
artikel
|
| 8 |
Hsp90 inhibition sensitizes DLBCL cells to cisplatin
|
Schmidt, Linnéa
|
|
|
89 |
4 |
p. 431-440
|
artikel
|
| 9 |
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study
|
Nelli, F.
|
|
|
89 |
4 |
p. 529-537
|
artikel
|
| 10 |
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors
|
Bagegni, Nusayba A.
|
|
|
89 |
4 |
p. 487-497
|
artikel
|
| 11 |
Population pharmacokinetics of crenolanib in children and young adults with brain tumors
|
Bisbee, Cora
|
|
|
89 |
4 |
p. 459-468
|
artikel
|
| 12 |
Somatic nuclear auto-antigenic sperm protein sensitizes human breast cancer cells to 5-Fluorouracil
|
Huang, Yanjing
|
|
|
89 |
4 |
p. 559-564
|
artikel
|
| 13 |
SOX8 promotes cetuximab resistance via HGF/MET bypass pathway activation in colorectal cancer
|
Piao, Hai-yan
|
|
|
89 |
4 |
p. 441-449
|
artikel
|
| 14 |
Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma
|
Yang, Zejia
|
|
|
89 |
4 |
p. 469-478
|
artikel
|
| 15 |
The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children’s Oncology Group and NRG Oncology study ARST1321
|
Gartrell, J.
|
|
|
89 |
4 |
p. 551-557
|
artikel
|
| 16 |
Unintentional combining enzalutamide with a moderate CYP2C8 inhibitor in a patient with metastatic castration-resistant prostate cancer: a case report
|
Verhulst, S. H.
|
|
|
89 |
4 |
p. 539-542
|
artikel
|
Tijdschrift beschrijving